Alumis Inc. (NASDAQ:ALMS – Get Free Report) has received an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $40.30.
Several equities research analysts have recently weighed in on the company. Wells Fargo & Company raised their target price on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Guggenheim upped their price target on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup reiterated a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th.
Get Our Latest Analysis on ALMS
Alumis Price Performance
Alumis (NASDAQ:ALMS – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. As a group, equities analysts anticipate that Alumis will post -2.87 EPS for the current year.
Insider Activity at Alumis
In related news, insider Sanam Pangali sold 5,000 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $28.00, for a total value of $140,000.00. Following the transaction, the insider directly owned 11,111 shares of the company’s stock, valued at $311,108. This trade represents a 31.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 33.70% of the stock is owned by company insiders.
Hedge Funds Weigh In On Alumis
Several large investors have recently bought and sold shares of ALMS. MPM Bioimpact LLC acquired a new stake in shares of Alumis during the fourth quarter worth about $23,443,000. Janus Henderson Group PLC purchased a new stake in shares of Alumis in the 1st quarter valued at about $46,790,000. Orbimed Advisors LLC acquired a new stake in shares of Alumis in the 2nd quarter valued at about $5,779,000. Woodline Partners LP grew its stake in Alumis by 809.7% during the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after buying an additional 1,558,660 shares during the last quarter. Finally, Samsara Biocapital LLC grew its stake in Alumis by 47.0% during the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock worth $14,404,000 after buying an additional 1,534,872 shares during the last quarter.
About Alumis
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
- Five stocks we like better than Alumis
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
